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Abstract
Bacterial resistance to b-lactams may rely on acquired b-lactamases encoded by class 1 integron-borne genes.
Rearrangement of integron cassette arrays is mediated by the integrase IntI1. It has been previously established that
integrase expression can be activated by the SOS response in vitro, leading to speculation that this is an important clinical
mechanism of acquiring resistance. Here we report the first in vivo evidence of the impact of SOS response activated by the
antibiotic treatment given to a patient and its output in terms of resistance development. We identified a new mechanism
of modulation of antibiotic resistance in integrons, based on the insertion of a genetic element, the gcuF1 cassette,
upstream of the integron-borne cassette blaOXA-28 encoding an extended spectrum b-lactamase. This insertion creates the
fused protein GCUF1-OXA-28 and modulates the transcription, the translation, and the secretion of the b-lactamase in a
Pseudomonas aeruginosa isolate (S-Pae) susceptible to the third generation cephalosporin ceftazidime. We found that the
metronidazole, not an anti-pseudomonal antibiotic given to the first patient infected with S-Pae, triggered the SOS response
that subsequently activated the integrase IntI1 expression. This resulted in the rearrangement of the integron gene cassette
array, through excision of the gcuF1 cassette, and the full expression the b-lactamase in an isolate (R-Pae) highly resistant to
ceftazidime, which further spread to other patients within our hospital. Our results demonstrate that in human hosts, the
antibiotic-induced SOS response in pathogens could play a pivotal role in adaptation process of the bacteria.
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Introduction
Transferable genes encoding antibiotic resistance to major
antibiotics (e.g. b-lactams, aminoglycosides) are often carried by
class 1 integrons in Gram negative pathogens [1]. In these genetic
elements the antibiotic resistance genes are carried inside mobile
structures called gene cassettes, which generally correspond to a
promoterless gene associated to a recombination site called attC,
formerly called 59-be [2,3]. Gene cassette expression is driven by a
promoter located in the integron platform upstream of the attI site,
the primary site of cassette integration, and in the case of the class
1 integron, inside the intI1 gene which encodes the cassette
recombinase [4]. This organization allows a positional regulation
of the cassette’s expression: the closer a gene cassette is located to
attI, the higher is its expression [1]. In addition to this
transcriptional attenuation along the cassette array, the decrease
in expression can be due to problems of translational coupling
[5,6]. Thus, gene expression in these elements can be modulated
by the site-specific recombination events mediated by the integrase
IntI1 [1,3].
The SOS response is a conserved regulatory network that is
induced in response to DNA damage [7]. It also promotes
integron rearrangements by controlling the expression of inte-
grases with promoters that contain a LexA-binding motif [8,9].
During the SOS response, the RecA protein, bound to single
stranded DNA, stimulates the cleavage of the repressor LexA, thus
releasing the transcription of the LexA-controlled genes. The
adaptations resulting from integron activity are thought to
influence bacterial evolution, especially in Proteobacteria, where
integrons are extremely common [3]. We have recently shown that
common horizontal gene transfer processes, such as conjugation
[10], trigger the SOS response and ultimately the integron
integrase expression. However, the most medically relevant SOS
induction is certainly the one directed by antibiotic treatments.
Hence, a number of antibiotics, including the b-lactams,
aminoglycosides and fluoroquinolones, have been found to directly
or indirectly provoke this stress response [11–13]. Despite this
evidence from in vitro studies, the clinical significance of the SOS
response on integron rearrangement and the dynamics of
integron-based bacterial adaptation during human infections are
unknown. So far, there are no examples of SOS-mediated
antibiotic resistance occurring during therapeutic use of antibiot-
ics, even though, as mentioned above, many of them stimulate the
SOS response.
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Here, we witnessed the emergence in a hospitalized patient of
an isolate of Pseudomonas aeruginosa highly resistant to the third
generation cephalosporin ceftazidime, associated with the produc-
tion of an extended-spectrum b-lactamase encoded by a class 1
integron-borne gene. This strain, highly resistant to ceftazidime,
further became epidemic within the hospital. We discovered the
mechanism, based on the excision of a gene cassette originally
located upstream of the b-lactamase-encoding gene cassette, which
modulated the expression of the transferable resistance gene. This
patient had been previously treated with ceftazidime (to treat the
infection by P. aeruginosa) and metronidazole (to treat an infection
by anaerobes). This led us to suspect the involvement of this
treatment in the integron cassette array remodeling, through SOS
response induction inside the patient. We demonstrated that the
metronidazole, not an anti-pseudomonal antibiotic, is able to
trigger the SOS response in P. aeruginosa, and subsequently
activates the integrase IntI1 and cassette rearrangement. Deletion
of the gcuF1 cassette and full expression the b-lactamase were
obtained at high rates in vitro, supporting this scenario to explain
the genesis, in the patient, of the R-Pae isolate from S-Pae after
metronidazole treatment.
Results
Enzymatic resistance mechanisms to b-lactams in an
epidemic multidrug resistant P. aeruginosa
We detected the same clone of a multi-drug resistant clone of P.
aeruginosa (R-Pae) in 13 adult patients by pulsed-field gel
electrophoresis (Figure S1). R-Pae was resistant to potent anti-
pseudomonal agents, including ceftazidime, cefepime, aztreonam,
aminoglycosides, and fluoroquinolones (Table S1). A double-disk
synergy test revealed a weak synergy between b-lactamase
substrates (ceftazidime or cefepime) and b-lactamase inhibitors
(imipenem or clavulanate) in these bacteria, suggesting production
of an extended-spectrum b-lactamase (oxacillinase) of Ambler class
D (Figure S2) [14]. We searched for the most common genes
encoding extended-spectrum oxacillinases in P. aeruginosa [15] by
PCR for the blaOXA-10, blaOXA-2 and blaOXA-1 groups [16]. Only
the PCR specific to blaOXA-10 using primers OXA-10A and B (see
Table S2) was positive. As blaOXA-10 and variants are found as
gene cassettes often borne by class 1 integrons [17], we performed
PCR experiments using primers specific to these integron
platforms, directed to the conserved sequences flanking the
variable cassette array, usually called 59-CS and 39-CS (see Table
S2). A single 1673-bp amplicon was thus obtained, which was
subsequently sequenced to reveal two resistance gene cassettes,
namely aacA4 that determines a 69-N-aminoglycoside acetyltrans-
ferase conferring high resistance to gentamicin and tobramycin
[18], and blaOXA-28 that encodes the extended-spectrum oxacilli-
nase OXA-28 [19] (Figure 1A). Additionally, quantification of the
specific mRNA transcripts by RT-qPCR showed that the R-Pae1
isolate overexpressed the ampC gene encoding the intrinsic
chromosomal cephalosporinase AmpC, when compared to the
wild type reference strain of P. aeruginosa PAO1 (Figure 2A).
To determine whether bacterial resistance had emerged during
the course of treatment, we retroactively analyzed the P. aeruginosa
isolates archived from the first colonized patient (patient 1) within
2 months before the isolation of R-Pae. The clonal strain S-Pae was
isolated from the sputum of patient 1, 28 days before the isolation
of R-Pae in the patient’s lung. R-Pae1 was isolated after a treatment
with ceftazidime (to treat the infection by P. aeruginosa) and
metronidazole (to treat an infection by anaerobes). To our
surprise, S-Pae was susceptible to ceftazidime (MIC, 4 mg/ml)
despite the presence of an intact blaOXA-28 gene in its genome
(Figure 1B, C). S-Pae and R-Pae1 demonstrated an equivalent
expression level of the cephalosporinase-encoding ampC
(Figure 2A). The other resistance mechanisms found in S-Pae
and R-Pae1 (efflux pump overproduction and porin loss) do not
alter the susceptibility to ceftazidime (see Text S1). Because of the
lack of evidence for classical resistance mechanisms accounting for
the difference in b-lactam susceptibilities in these isolates, we
investigated the possible mechanism of resistance modulation.
OXA-28 oxacillinase production in R-Pae1 and S-Pae
S-Pae differed from R-Pae1 by a 10-fold lower amount of blaOXA-
28 transcripts (Figure 2B) and by the presence of a 319-bp cassette,
gcuF1, inserted immediately upstream of blaOXA-28 (Figure 1B).
Using nested-PCR, we demonstrated the presence of free circular
cassettes of gcuF1 in S-Pae (Figure 3A, B), demonstrating that the
recombination between its own attC site and the aacA4 attC site was
occurring, though at extremely low level [2]. Computational
analysis of the nucleotide sequence of the S-Pae integron predicted
the translation of a new ORF, a fused protein consisting of gcuF1
and blaOXA-28 (GCUF1-OXA-28). We were able to show that
these two cassettes (gcuF1 and blaOXA-28) could be transcribed in a
single transcript. Hence, we could retrieve a specific amplicon after
PCR amplification using cDNA prepared from S-Pae RNA as the
matrix and with primers overlapping the junction between gcuF1
and blaOXA-28 (Figure S3). The GCUF1-OXA-28 peptide (368
residues) was predicted to have a molecular weight of 40.1 kDa,
compared with the 29.3-kDa native OXA-28 (266 residues). To
confirm these data, both ORFs were expressed in Escherichia coli
BL21 from plasmid pET-28a which adds an N-terminal polyHis
tag. After purification, we found that their molecular weights
estimated by SDS-PAGE were in full agreement with our
predictions (Figure 1D). This protein contained the original 19-
residue long signal peptide now misplaced between the GCUF1
and the OXA-28 domains at position 103–121 of the GCUF1-
OXA-28 protein (Figure 1B and 4A). Since b-lactamases are
periplasmic proteins and are produced as preproteins with an N-
terminal peptide signal [20], one would expect that the
misplacement of the signal peptide in the GCUF1-OXA-28
protein will abolish the periplasmic process of the b-lactamase.
Author Summary
The bacterial SOS response is a conserved regulatory
network that is induced in response to DNA damage. Its
activation in vitro leads to the emergence of resistance to
antibiotics, leading to speculation that this is an important
clinical mechanism of acquiring resistance. We found
evidence here that antibiotic-induced SOS response plays
a role in bacterial genome rearrangement in vivo within
humans. The major classes of antibiotics can trigger the
bacterial SOS response and our data raise questions about
their wide use and their subsequent effect on the bacterial
genetic adaptability. This suggests that emergence of
antibiotic resistance during therapy could be reduced by
inhibiting the bacterial SOS response. We showed that
acquired resistance genes could spread latently in suscep-
tible bacterial strains until needed. These findings could
impact current policies for control of antibiotic resistance,
which rely on the detection of resistant bacteria and on
the assumption that resistance mechanisms have a
functional cost to the bacteria. More generally, SOS
response may spur changes in the behavior of bacteria
and their faster adaptation to hostile environments,
including humans.
SOS Response and Antibiotic Resistance in Patient
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Figure 1. gcuF1 cassette insertion modulates the resistance to ceftazidime. (A) Schematic representation of the class 1 integron carried by
R-Pae1 and laboratory M-Pae mutants obtained from S-Pae and (B) carried by S-Pae, with the 319 bp gcuF1 cassette. Open arrows represent the
coding sequences and indicate the direction of transcription. The purple box indicates the LexA box. The attI1 site is shown by the red box and
colored triangles indicate the cassette attC sites. The black rectangles indicate the peptide signal sequences encoded in blaOXA-28. The genes intI1,
aacA4 and blaOXA-28 encode the integrase IntI1, the aminoglycoside acetyltransferase AAC(69)-Ib and the extended-spectrum oxacillinase OXA-28,
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However, cellular production of this altered protein conferred a
residual resistance to ceftazidime (MIC of ceftazidime, 8 mg/ml;
gcuF1-blaOXA-28 in Figure 1C), suggesting the presence of an active
and processed OXA-28 in the periplasm of the GCUF1-OXA28-
producing isolate. To clarify this point, we cloned the blaOXA-28
and gcuF1-blaOXA-28 sequences into the broad host range vector
pBTK27 to encode C-terminal His-tagged polypeptides that were
expressed in the reference strain P. aeruginosa PA14DampC.
Western-blot analysis of periplasmic extracts of GCUF1-
OXA28-producing bacteria revealed the presence of a reduced
amount of processed periplasmic OXA-28 (Figure 1D), consistent
with the lower resistance to ceftazidime when the gcuF1 cassette is
inserted upstream of the blaOXA-28 (Figure 1C). We used a directed
mutagenesis approach to clarify the origin of periplasmic OXA-28
in S-Pae and determine whether it is due to the export processing
of the fusion protein or to an internal translational initiation at the
original OXA-28 start codon (Figure 4A). In P. aeruginosa
PA14DampC carrying a plasmid-borne gcuF1-blaOXA-28, the in-
frame insertion of a stop codon just upstream of blaOXA-28 reduced
the resistance level to ceftazidime down to 2 mg/ml. We also tested
the effect of the in frame deletion of the blaOXA-28 ribosome
binding site (GAAGGT), or its substitution by a sequence with no
ribosome binding properties (CTCTCT). Finally, we tested the
substitution of the ATG start codon with either a GTC or a GTG
valine codons, which have no or weak translation initiation power
[21]. None of these mutations led to a change in resistance level
(Figure 1C). Hence, we confirmed that detected OXA-28 came
entirely from the processing of the ORF2-OXA28 fusion protein,
and that the inefficiency of its maturation was in part responsible
for the low resistance level to ceftazidime. Additionally, the
putative ribosome binding site of gcuF1 (TTAGG) is predicted to
have a poor translation initiation efficiency [22,23] (Figure 4A),
likely leading to reduced translation of gcuF1-blaOXA-28.
SOS response induction by metronidazole treatment
In patient 1, the transition from S-Pae to R-Pae1 was observed
after treatment with two antibiotics, ceftazidime and metronida-
zole, both known to activate the bacterial SOS response [12,24].
Cassette expression in class 1 integrons can be controlled by two
promoters, Pc and P2, which can exist under various forms [4]. P2
is created by the insertion of three guanines between the potential
235 and 210 regions, but this insertion also disrupts the LexA
binding box (also called the SOS box) of the intI1 promoter and
abrogates the SOS control of intI1 expression [4]. Analysis of the
S-Pae class 1 integron revealed a functional LexA-binding box
overlapping the 210 box of the intI1 promoter [25], thus the P2
promoter is absent and the cassettes’ expression only relies on the
respectively. The nucleotide sequences reported here appear in the EMBL/Genbank nucleotide sequence database under accession no. FJ207466 (S-
Pae) and FJ374756 (R-Pae1). (C) Susceptibility to ceftazidime of P. aeruginosa reference strain PA14 (WT), S-Pae, R-Pae1, laboratory ceftazidime-
resistant mutant obtained from S-Pae (M-Pae) and PA14DampC carrying the empty vector pBTK27 (Vector control), cloned gcuF1-blaOXA-28 (gcuF1-
blaOXA-28), cloned blaOXA-28 (blaOXA-28) and with site-directed mutations in gcuF1-blaOXA-28: TGA stop codon inserted downstream of gcuF1 (InsSTOP),
GAAGG ribosome binding site deleted upstream of blaOXA-28 (DelRBS) or substituted with a sequence with no translation initiation power (ReplRBS)
and with the blaOXA-28 ATG start codon replaced by GTC (ReplATG1) or GTG (ReplATG2). Means 6 SEM (n= 3). Numbers above bars are MICs of
ceftazidime. (D) Left pane: Insertion of gcuF1 creates a new ORF. SDS-PAGE analysis of purified N-terminal His-tagged GCUF1-OXA-28 and OXA-28
from E. coli. Right pane: Insertion of gcuF1 reduces the amount of processed periplasmic OXA-28. SDS-PAGE analysis of periplasmic extracts (10 mg of
total proteins) from reference strain P. aeruginosa PA14DampC producing C-terminal His-tagged GCUF1-OXA-28 and OXA-28 (relative band intensities
are indicated under the bands). Molecular weights are indicated in kDa.
doi:10.1371/journal.ppat.1002778.g001
Figure 2. gcuF1 excision enhances the expression of blaOXA-28.
The mRNA levels of genes are given. Means 6 SEM (n$2, two-sided
Student’s t-test; NS, P.0.05; ***, P,0.001). Transcripts of gene ampC (A)
and blaOXA-28 (B) were quantitatively assessed by RT-qPCR. The mRNA
levels of genes were normalized to that of reference gene rpsL and
expressed as a ratio to the levels in the R-Pae1 isolate (for blaOXA-28) or
in the wild-type PA14 (for ampC) in which the values were set at 1.00.
doi:10.1371/journal.ppat.1002778.g002
Figure 3. gcuF1 gene cassette exists in free circular form. (A)
Position and direction of primers used for amplification (Table S2) are
indicated by arrows. (B) Visualization of the PCR products on an agarose
gel (resulted from the nested PCR with primers circ3 and circ4). PCRs
were performed using total DNA from isolates R-Pae1 (without gcuF1,
taken as a negative control) and S-Pae (with gcuF1) as templates. MW:
Molecular weight.
doi:10.1371/journal.ppat.1002778.g003
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strong Pc promoter variant PcS (Figure 4B). It has been previously
found that the encoded integrase IntI1 (IntI1R32_N39) displayed the
second highest excision activity of the four known existing variants
[4]. In agreement with this, using nested-PCR, we confirmed the
presence of free circular gcuF1 cassettes in S-Pae (Figure 3A, B),
occurring through recombination between its own attCgcuF1 site and
the aacA4 attCaacA4 site, as observed previously for a few other
cassettes [2]. LexA is the transcriptional repressor that binds the
SOS box sequences to silence transcription. RecA, once activated
by the presence of abnormal single strand DNA produced by a
variety of stimuli that includes antibiotic exposure, induces the
LexA autoproteolysis and releases the transcriptional silencing
driven by LexA binding to SOS boxes. We hypothesized that the
excision of the gcuF1 cassette by the integrase IntI1 and subsequent
emergence of full resistance to ceftazidime in R-Pae1 was a result
of the SOS response induced by antibiotic therapy in the patient.
We quantified the expression of SOS pathway genes recA and
lexA, as well as the integrase encoding gene intI1 by RT-qPCR
after in vitro induction with metronidazole and ceftazidime. Our
results indicated that in vitro exposure of S-PaeDampC to the
Figure 4. Details of the class 1 integron sequence from isolate S-Pae. (A) Nucleotide sequence of the 319-pb gcuF1 cassette. Cassette
boundaries are indicated by slashes. The putative ribosome binding site (RBS) and start codon of gcuF1-blaOXA-28 are indicated by a grey box and by a
red arrow, respectively. The deduced amino acid sequence of the N-terminal portion of GCUF1-OXA-28 is designated in single-letter code below the
nucleotide sequence. The attC recombination site of the gcuF1 cassette is indicated in light green. The inverted repeats (R0, L0 and L9, R9) are indicated
by light blue arrows. The putative original RBS and start codon of blaOXA-28 are indicated by a grey box and a red arrow, respectively. Mutated
nucleotides are underlined. The signal peptide is indicated in pink and the cleavage site by an open triangle. (B) A putative LexA protein binding site
was identified in the promoter region of the IntI1 integrase. The LexA protein binding site consensus (CTGTN8ACAG) is indicated in purple [7]. The
putative s70 promoter elements (235 and 210) of PcS and Pint are shown in yellow and the intI1 59 region is indicated in green.
doi:10.1371/journal.ppat.1002778.g004
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minimal inhibitory concentration of ceftazidime (2 mg/ml) neither
triggered the SOS response (recA and lexA were not induced), nor
enhanced the expression of the intI1 gene (Figure 5A). We
measured the frequency of ceftazidime-resistant mutant emer-
gence by gcuF1 cassette excision in the same experimental
conditions. Consistent with the integrase expression data, we
found that the gcuF1 cassette excision frequency remained basal
after exposure to ceftazidime (Figure 5B). On the contrary, in vitro
exposure of S-PaeDampC to therapeutic concentrations of metro-
nidazole (50 mg/ml for recA wild-type strain and 25 mg/ml for recA
mutants) triggered the SOS response, as indicated by the increased
recA and lexA expression, and the increase in intI1 expression, gcuF1
cassette excision and a subsequent 34-fold enhancement of the
frequency of emergence of ceftazidime-resistant mutants
(Figure 5A, B). As shown with the results obtained in recA-deleted
and recA-complemented strains, the effect of metronidazole on the
integron rearrangement fully depended on the presence of recA,
confirming the role of the SOS induction for the cassette
rearrangement (Figure 5A, B). In mutants isolated both in patient
1 (R-Pae1) and in vitro (M-Pae), the gcuF1 cassette excision provoked
full blaOXA-28 expression and a massive increase in resistance to
ceftazidime (Figure 1C).
Discussion
In this study, we identified a new mechanism of modulation of
antibiotic resistance in integrons. The positional regulation of gene
cassette expression was already documented, but this was considered so
far as only relying on the transcription attenuation process and on the
lack of transcriptional coupling between genes carried in consecutive
cassettes [6]. What we describe here is the presence of a genetic
element, the gcuF1 cassette, upstream of the integron-borne b-
lactamase cassette blaOXA-28 which modulates the transcription,
translation, and secretion of this enzyme, all at once. The poor
ribosome-binding site found upstream of gcuF1 (Figure 4A) [23] is likely
responsible for the low production of the fusion protein detected, but is
also likely responsible for the low level of blaOXA-28 mRNA. Indeed, it
has been shown that a reduced ribosome binding to RBS can
destabilize mRNA, which then becomes more vulnerable to endonu-
cleolytic attack [26]. GcuF1 shares 78% identity with integron-borne
orfD gene cassettes of unknown function that are frequently found in
clinical strains of Pseudomonas sp. and Enterobacteriaceae [1]. The insertion
of gcuF1 generates a fusion protein GCUF1-OXA-28 with a misplaced
signal peptide between the GCUF1 and the OXA-28 domains.
However, the GCUF1-OXA-28-producing bacteria still demonstrated
residual resistance to ceftazidime, consistent with the presence of small
amount of the processed OXA-28 in its periplasm. Using various
mutants constructed in this aim, we established that the OXA-28
produced from gcuF1-blaOXA-28 was exclusively derived from cleavage
at position 121 of the fusion protein GCUF1-OXA-28 (Figure 4A).
These data confirm that a protein with a misplaced cleavable leader
sequence (i.e. outside the N-terminus) can be exported, although less
efficiently, into the periplasm [27].
We showed that the gcuF1 cassette can be excised by the IntI1
integrase, leading to the production of a circularized cassette. The
gcuF1 cassette carries an attC site with an unusual R0 box, with a T
instead of a C in last position, as in the large majority of integron
cassettes (Figure 4A). The gcuF1 closest relative is a cassette found
in the Acidovorax sp. JS42 genome (GenBank accession number
CP000539), which is 87% identical over the whole cassette
sequence, but shows a CC at this precise position. Thus the
substitution of this dinucleotide by a single T explains why the
spacer between the R0 and L0 boxes is reduced to 4 nucleotides,
instead of the usual 5 nucleotides in gcuF1 (Figure 4A). The last
base of R0 is normally pairing with the first base of the R9 box in
the single strand recombinogenic form of the attC site [28].
Frumerie and colleagues tested all possible base pairs (C/G, A/T,
G/C and T/A) at this position in the predicted annealed R0/R9,
and found that all deeply decreased the recombination rate, by
more than a hundred fold factor [29]. However the effect of single
base substitutions at these positions is so far unknown, the
observations made in our study suggest that substitution of the
conserved C in R0 by a T does not abolish the attC recognition and
recombination, but the effect of this mutation, as well as the one
brought by the R0/L0 spacer reduction, on the rate of
recombination needs to be established.
We found that excision of the gcuF1 cassette from the original
cassette array leads to increased resistance to ceftazidime
(Figure 1C). As the expression of IntI1 is controlled by the SOS
response, we surmised the antibiotic treatment given in first
instance to this patient (ceftazidime and metronidazole) to be
responsible for the SOS induction episode that ultimately led to
the IntI1-mediated gcuF1 deletion. We found that, in contrast to
ceftazidime, in vitro exposure to therapeutic concentrations of
metronidazole, an antimicrobial against which P. aeruginosa is
naturally resistant, greatly enhanced the frequency of emergence
of ceftazidime-resistant mutants. This phenotype is dependent on
the excision of the gcuF1 cassette that is fully dependent on the
SOS response, as attested by the lack of excision in a recA mutant
(Figure 5B). We speculate that in patient 1, metronidazole likely
promoted the SOS-dependent transition from S-Pae to R-Pae1,
which was further selected by ceftazidime therapy.
Interestingly, Cipriano Souza et al. showed that previous
consumption of metronidazole was an independent risk factor
for acquisition of multi-drug resistant P. aeruginosa by hospitalized
patients [30]. Metronidazole and related 5-nitroimidazoles are
redox-active prodrugs. Metronidazole is widely used to treat
anaerobic bacteria infections, (e.g. Clostridium difficile), protozoa, and
the microaerophilic Helicobacter pylori [31]. Bacterial nitroreduc-
tases, such as RdxA in H. pylori, catalyze the conversion of
metronidazole to mutagenic products that directly interact with
DNA bases [32,33]. This causes DNA helix destabilization and
single- and double-strand DNA breakage [34] that activate the
SOS response [7,24]. The effect of metronidazole in P. aeruginosa,
in terms of DNA damage has still to be established, but one can
speculate that the RdxA homolog in P. aeruginosa (PA5190 in the
PAO1 genome, http://www.pseudomonas.com) could play a
similar role in the metabolism of the metronidazole, and explain
how this antibiotic triggers the SOS induction.
Our data suggest that SOS induction by antibiotics can result in
the development of integron-based resistance in vivo. SOS also
enhances the rate of mutations [7]. This is of particular concern in
P. aeruginosa in which multidrug resistance mainly arise from
chromosomal mutations [35]. More generally, it may lead to
undesired changes in the behavior of bacteria and their faster
adaptation to hostile environments. This is alarming because apart
from metronidazole, other major classes of antibiotics (e.g. b-
lactams, aminoglycosides, trimethoprim and fluoroquinolones) can
trigger the bacterial SOS response [11–13].
The expression of horizontally acquired antibiotic resistance
mechanisms is tightly regulated; this may reduce the biological cost
associated with resistance expression and account for the dissemina-
tion of susceptible strains carrying hidden resistance determinants
[36,37]. Here, in S-Pae, expression of antibiotic resistance is silenced
until antibiotic exposure triggers expression. This could represent an
efficient evolutionary pathway for resistance determinants to be
‘‘switchable’’ and render bacteria fitness-neutral in the absence of
antibiotic selection pressure [37]. Current policies for controlling the
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spread antibiotic resistance often rely on the detection of resistant
bacteria, and on the assumption that resistance has a functional cost
[38]. Future antibiotic restriction guidelines should consider the fact
that resistance genes can spread latently in susceptible isolates with
low biological cost.
In summary, we describe a reversible mechanism modulating an
acquired antibiotic resistance in bacteria. The metronidazole-
induced SOS response favored the emergence in a patient of
bacteria highly resistant to ceftazidime that could then spread to
twelve other patients which were under antibiotic pressure.
The suppression of the SOS response activation has been reported
to enhance killing by antibiotics of E. coli and to increase survival of
infected mice [39,40]. Efforts have been made to identify small
molecules and short peptides that inhibit RecA activity, although the
absence of potential adverse effects on Rad51 (the human RecA
homologue) needs to be demonstrated [41–43]. Our results suggest an
adaptive role for the antibiotic-induced SOS response in bacterial
genome rearrangement in vivo within humans. Altogether, this supports
the hypothesis that inhibition of RecA is a plausible therapeutic
adjuvant in combined therapy to reduce the capacity to generate
antibiotic-resistant mutants.
Materials and Methods
Bacterial isolates
We identified a multidrug-resistant P. aeruginosa strain (R-Pae) in
13 patients hospitalized in the hematological ward of the
University Hospital of Besanc¸on (France) from March 2004
Figure 5. Metronidazole increases the emergence of ceftazidime-resistant mutants by inducing the SOS response. (A) Expression
determination by RT-qPCR of recA, lexA and intI1 with mitomycin C (a well-characterized SOS inducer used as a positive control [8]), metronidazole
and ceftazidime in S-PaeDampC (WT), S-PaeDampCDrecA (DrecA) and S-PaeDampCDrecA complemented with recA (recA+). Ratio of means6 SEM from
at least 2 independent experiments in triplicate; two-sided Student’s t-tests using 1.0 – dotted line – as comparator; NS, P.0.05; **, P,0.01; ***,
P,0.001. (B) Frequency of emergence of ceftazidime-resistant mutant (by gcuF1 cassette excision) in the same experimental conditions as for
Figure 5A (ratios of geometric means of the excision rates 6 SEM, N$3; two-sided Student’s t-tests using 1.0 – dotted line – as comparator; NS,
P.0.05; ***, P,0.001).
doi:10.1371/journal.ppat.1002778.g005
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(Patient 1) to December 2009 (Patient 13). The genetic similarity
of P. aeruginosa clinical isolates was investigated by pulsed field gel
electrophoresis (PFGE; CHEF-DR III; Bio-Rad, Hercules, Cali-
fornia) with the use of DraI enzyme, as described elsewhere [44].
We retroactively analyzed the bacterial isolates of patient 1’s early
specimens. Twenty-eight days before pulmonary infection with R-
Pae1, this patient was colonized with S-Pae, a clonally-related
isolate that was more susceptible to b-lactams than R-Pae. Early
and late sputums only contented S-Pae and R-Pae, respectively. In
review of the patient record, patient 1 was treated with ceftazidime
(4 g/day for 8 days) for P. aeruginosa and also with metronidazole
(500 mg/day for 7 days) for infections by anaerobes prior to the
isolation of R-Pae1. Oligonucleotides, bacterial strains and
plasmids used for this study are detailed in the Tables S2, S3
and S4, respectively.
Determination of the resistance level to antibiotics
Theminimal inhibitory concentrations (MICs) of selected antibiotics
were determined by the conventional Mueller-Hinton agar (MHA)
dilution method, and interpreted according to CLSI (Clinical and
Laboratory Standards Institute) guidelines [45]. The wild-type
reference strain of P. aeruginosa PA14 was used as a control in
susceptibility testing. MHAwas supplemented with 1 mMof IPTG for
strains carrying pBTK27 derivatives (Table S4).
Real time quantitative RT-PCR (RT-qPCR)
Total RNA was isolated from cultures at an absorbance at 600 nm
of 1.0 (or otherwise stated) using the Qiagen RNeasy protocol (Qiagen,
Valencia, California). The RNA samples were treated with DNase
(TurboDNAse; Ambion, Austin, Texas) and further cleaned according
to the manufacturer’s protocol. Total RNA was quantified using the
RiboGreen RNA Quantitation Kit (Molecular Probes, Carlsbad,
California). Total RNA was reverse transcribed with Superscript III
reverse transcriptase (Invitrogen, Carlsbad, California) as specified by
the supplier. Quantitative PCR was performed on an Mx4000
Multiplex QPCR System (Stratagene, Santa Clara, California) using
samples in triplicate with 25 ng of total RNA in a 20 ml reaction using
SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad,
California) and specific primers for housekeeping gene rpsL, blaOXA-28,
ampC, recA, lexA, and intI1 (Table S2). PCR cycling conditions consisted
of 95uC for 10 min, and 40 cycles of 95uC for 15 s, 60uC for 1 min.
After each assay, a dissociation curve was run to confirm specificity of
all PCR amplicons. The mRNA levels of ampC and blaOXA-28 were
normalized to that of reference gene rpsL [46] and expressed as a ratio
to the levels in the isolate PA14 (for ampC) or R-Pae1 (for blaOXA-28) in
which the values were set at 1.00. For recA, lexA, and intI1 genes,
resulting Ct values were converted to nanograms, normalized to total
RNA and expressed as the average of triplicate samples.
Evidence of circular forms of gcuF1 cassette
We assessed the presence in S-Pae isolate of free circular forms
of the gcuF1 cassette. Total DNA from isolates R-Pae1 (without
gcuF1, taken as a control) and S-Pae (with gcuF1) were PCR
amplified with primers circ1 and circ2 (Figure 3A, Table S2). The
purified PCR products were used as templates for a second nested
PCR with primers circ3 and circ4. PCR products were visualized
on an agarose gel. The PCR fragment obtained from S-Pae DNA
was further sequenced to verify its specificity.
Evidence of gcuF1-blaOXA-28 transcripts
To determine whether the DNA element gcuF1-blaOXA-28 could
transcribe a functional transcript, we carried out RT-PCR
reactions by using PCR primers overlapping the gcuF1-blaOXA-28
junction (overlap1 and overlap2, Table S1), and cDNA prepared
from S-Pae RNA as the matrix (see above). The nucleotide
sequence of the amplicon was determined to check for the
specificity of the reaction.
Deletion mutant construction
For the deletion of ampC from PA14 and S-Pae, approximately
1000-bp specific fragments upstream (with primers AmpCdel1F/
AmpCdel1R) and downstream (with primers AmpCdel2F/
AmpCdel2R) of ampC were PCR amplified from PA14 and S-
Pae total DNAs, and used in an overlap extension reaction to
create a single 2,000-bp product (Table S1). These products were
cloned into Gateway-compatible gene replacement vector pEX18-
AmpGW [47], yielding the plasmids pDelAmpC-PA14 and
pDelAmpC-SPae (Table S3), which were then transformed into
E. coli DH5a.
For recA inactivation in S-PaeDampC, 59 (ca. 450-bp) and 39 (ca.
530-bp) portions of recA were amplified separately with primer
pairs RecAdel1F/RecAdel1R and RecAdel2F/RecAdel2R, re-
spectively. The tetA gene was amplified from plasmid mini-CTX1
with primers TetF and TetR (Table S1). These three fragments
were cloned simultaneously in a 4 way ligation in the EcoRI/
HindIII sites of pEX18ap to yield plasmid pDelRecA (Table S3).
The plasmids for ampC or recA deletion were transferred into the
recipient strains (PA14 or S-PaeDampC) by triparental mating that
included the donor strain E. coli DH5a with strain E. coli HB101
(containing helper plasmid pRK2013), followed by selection with
irgasan (25 mg/ml) and carbenicillin (150 mg/ml for PA14,
500 mg/ml for S-PaeDampC) and screening for P aeruginosa
transconjugants with the deletion as previously described [48].
Deletion of the ampC and inactivation of recA were verified by PCR
and sequencing.
Construction of plasmids expressing blaOXA-28 and
derivatives
The resistance level to ceftazidime conferred by the production
of OXA-28, GCUF1-OXA-28, and their derivatives was assessed
by cloning gcuF1-blaOXA-28 (PCRed from S-Pae with primers 1 and
3) and blaOXA-28 (PCRed from R-Pae1 with primers 2 and 3)
sequences into the broad host range vector pBTK27. This yielded
plasmids pBTK/gcuF1-oxa28 and pBTK/oxa28, respectively,
encoding C-terminal polypeptides that were expressed in the
reference strain P. aeruginosa PA14DampC (Table S3). We used the
plasmid pBTK/gcuF1-oxa28 as template for various mutageneses
with a QuikChange kit (Stratagene). We inserted a TGA stop
codon downstream gcuF1 with mutagenic primers stop-F and stop-
R, yielding plasmid pInsSTOP. We deleted in frame the
GAAGGT sequence including the natural blaOXA-28 ribosome
binding site (GAAGG) with mutagenic primers delRBS-F and
delRBS-R, yielding plasmid pDelRBS, which encodes this
GCUF1-OXA-28 variant missing amino acids E100 and G101.
We also substituted the sequence harboring the blaOXA-28
ribosome binding site with a sequence with no translation
initiation power (GAAGGT by CTCTCT) using mutagenic
primers replRBS-F and replRBS-R, yielding plasmid pReplRBS.
The ATG start codon from blaOXA-28 was substituted by GTC or
by GTG with mutagenic primers (RepATG1-F/RepATG1-R and
RepATG2-F/RepATG2-R, respectively) yielding plasmid pRe-
plATG1 and pReplATG2, respectively, which encodes the
M103V GCUF1-OXA-28 variant (Tables S2 and S4). All
pBTK27-derivated plasmids were introduced into the reference
strain P. aeruginosa PA14DampC by triparental mating (see above) to
assess the resistance to ceftazidime.
SOS Response and Antibiotic Resistance in Patient
PLoS Pathogens | www.plospathogens.org 8 June 2012 | Volume 8 | Issue 6 | e1002778
OXA-28 and GCUF1-OXA-28 purification
To determine the size of the encoded proteins, blaOXA-28
(PCRed from R-Pae1 with primers 5 and 6) and gcuF1-blaOXA-28
sequences (PCRed from S-Pae with primers 4 and 6) were cloned
into the pET-28a vector (Kmr; Novagen-Merck, Darmstadt,
Germany) at NheI/XhoI, yielding plasmids pET/oxa28 and
pET/gcuF1-oxa28, respectively, encoding N-terminal His-tagged
polypeptides. The cloned gene products were expressed in E. coli
BL21(DE3) by IPTG induction (0.2 mM) to the exponentially
growing cells (A600 of 0.8) and left overnight at 20uC with shaking.
Bacteria were harvested and lysed using standard protocols. The
lysates were applied on a 5 ml Ni-NTA column (Qiagen). His-
tagged peptides were eluted with PBS supplemented with 250 mM
imidazole. Eluted fractions were separated by 12% SDS-PAGE
and transferred to nitrocellulose filters. Filters were hybridized
with the His-detector Ni-HRP reagent (KPL) and the immune
complexes were detected by the ECL-Plus chemiluminescent
system (GE Healthcare, Buckinghamshire, United Kingdom).
OXA-28 and GCUF1-OXA-28 subcellular localization
To assess the presence of His-tagged OXA-28 or GCUF1-
OXA-28 in the periplasm, the plasmids pBTK/oxa28 or pBTK/
gcuF1-oxa28 in P. aeruginosa PA14DampC was induced by 1 mM
IPTG for 4 h at 37uC. Periplasmic fractions were prepared by
using Peripreps Periplasting kit (Epicentre Biotechnologies,
Madison, Wisconsin) and analyzed by SDS-PAGE, transfer, and
hybridization (see below). The raw integrated density of the blots
was assessed using the ImageJ 1.44p software (National Institute of
Health).
Construction of plasmid expressing recA
We cloned recA (PCRed from S-Pae with primers RecA1 and
RecA2) sequence into the broad host range vector pBTK27,
yielding plasmid pBTK/recA (Tables S2 and S4). Plasmid pBTK/
recA was introduced into the strain S-PaeDampCDrecA by
triparental mating (see above).
Frequency of emergence of ceftazidime-resistant
mutants by gcuF1 cassette excision
S-PaeDampC, S-PaeDampCDrecA, and S-PaeDampCDrecA carrying
pBTK/recA or pBTK27 plasmids were used to determine the
frequency of emergence of ceftazidime-resistant mutants by gcuF1
cassette excision. The gene ampC was deleted to avoid the
emergence of resistant mutants overproducing this intrinsic b-
lactamase. Bacteria were grown in LB broth (Luria-Bertani)
overnight, then diluted 1:250 and grown until OD600 = 0.3. Half of
the cultures were then exposed to antibiotics (mitomycin C, 1 MIC
for 1.5 h; ceftazidime, 1 MIC for 1 h; metronidazole, 1/40 MIC
for 15 h). MICs of mitomycin C were 1.0/0.3 mg/ml, those of
ceftazidime were 2/2 mg/ml and those of metronidazole were
2000/1000 mg/ml for S-Pae derivatives with or without the recA
gene, respectively. Exposure to antibiotics in these conditions did
not alter the growth rates of the bacteria. Metronidazole
concentrations used for SOS response induction experiments (25
and 50 mg/ml) were in the range of those found in the plasma of
treated patients [49]. Cultures were collected by centrifugation
and washed twice with 0.9% NaCl. Appropriate dilutions in 0.9%
NaCl were plated on MH plates with or without ceftazidime at
50 mg/ml. We checked the gcuF1 excision by PCR in 133 clones
growing on ceftazidime-containing media, obtained after exposure
to mitomycin C, metronidazole and ceftazidime. Only one of them
(0.8%) still displayed the gcuF1 cassette. The gcuF1 excision rate
under antibiotic stress was then estimated as the number of
ceftazidime-resistant colonies divided by the number of plated
cells. The result was expressed as the ratio of the excision rates
with and without antibiotic (for wild-type and DrecA strains) and
with or without recA (for recA-complemented strain). All assays were
independently performed at least 3 times. All the samples were
subjected to microscopic observation to ascertain that no
filamented cells were present. We confirmed that the isolate S-
Pae was not a hypermutator (see Text S1).
Ethics statement
Approval and written informed consent from all subjects or
their legally authorized representatives were obtained before study
initiation. The study was approved by the ethical committee
‘Comite´ d’Etude Clinique’ of the Besanc¸on hospital, Besanc¸on,
France.
Statistical analysis
Student’s t-tests were used to determine statistical significance
for comparisons of gene expression (Figure 5A) and frequencies of
emergence of ceftazidime-resistant mutants (by gcuF1 excision;
Figure 5B) with and without antibiotic (for wild-type and DrecA
strains) and with or without recA (for recA-complemented strain).
Data were log transformed and variance estimates were pooled
over similar experiments, resulting in pooled estimates of standard
error of 0.24 with 65 degrees of freedom for the t-tests of Figure 2A
and of 0.54 with 27 degrees of freedom for the t-tests of Figure 5B.
Graphical examination supports the assumption of normality and
homogeneous variation across experiments for the gene expression
data Figure 5A and frequency the emergence of ceftazidime-
resistant mutant data Figure 5B expressed on a log scale. The
chosen significance threshold was 0.05 for all tests.
Supporting Information
Figure S1 The spread of a multi-drug resistant strain of
R-Pae producing the extended-spectrum b-lactamase
OXA-28. Pulsed-field gel electrophoresis profiles of DraI-digested
DNA from P. aeruginosa isolates that were recovered from 13
patients in the Hematological ward of the University Hospital of
Besanc¸on (France) from March 2004 (isolate R-Pae1) to December
2009 (isolate R-Pae13). S-Pae was isolated from patient 1, 28 days
before R-Pae1.
(TIFF)
Figure S2 Double-disk synergy test with P aeruginosa
isolate R-Pae1 producing the extended-spectrum b-
lactamase OXA-28. Diffusion test was performed on Mueller-
Hinton agar [14]. Synergies were observed between disks
containing the substrates cefepime (30 mg in the FEP disk) or
ceftazidime (30 mg in CAZ disk) and (A) the oxacillinase inhibitors
clavulanate (10 mg in the amoxicillin/clavulanate AMC disk) or (B)
imipenem (10 mg in the IMP disk). Such synergies are usually
noticed with P aeruginosa strains producing class A extended-
spectrum b-lactamases and class D extended-spectrum oxacilli-
nases [14].
(TIFF)
Figure S3 The gcuF1-blaOXA-28 element allows the
transcription of a single transcript. Electrophoresis on 1%
agarose of PCR products using primers overlapping the junction
gcuF1-blaOXA-28 (overlap 1 and overlap2, see Table S1). Templates
were as follows: genomic DNA of R-Pae (1) and S-Pae (2), RNA
extract of S-Pae (3), cDNA obtained from S-Pae RNA (4), water (5).
MW: Molecular weight (1 kb band is indicated).
(TIFF)
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Table S1 Resistance levels to antibiotics in the studied
isolates of P. aeruginosa.
(DOC)
Table S2 List of primers used in this study.
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Table S3 List of bacterial strains used in this study.
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Table S4 List of plasmids used in this study.
(DOC)
Text S1 Identification of additional non-enzymatic
resistance mechanisms to b-lactams, and determination
of the hypermutator phenotype of S-Pae.
(DOC)
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